The Sovereign AI fund is providing funding and compute capacity to Potential Sciences.

UK start-up Potential Sciences emerged from stealth today with a sizeable seed funding round and an ambition to transform drug discovery with AI.

The UK government's £500 million Sovereign AI fund is close to making another strategic investment, this time in Potential Sciences, a drug discovery startup that uses artificial intelligence to accelerate the identification of new molecules and therapies. According to Sky News, Sovereign AI is anchoring a funding round for the company and, if the deal goes through, Potential Sciences will join a small group of early-stage firms that have already received backing from the fund. As part of the arrangement, Josephine Kant, Sovereign AI's head of ventures, is expected to join the Potential Sciences board. The startup's platform relies on sophisticated data analysis and statistical methods to discover drug candidates more quickly than traditional approaches, a capability that has attracted interest from pharmaceutical companies seeking to shorten development timelines. In addition to providing seven-figure capital, Sovereign AI is reportedly committing access to national compute resources, reflecting the fund's broader strategy of offering more than just cash. So far, the government vehicle has announced investments in other AI companies, including Olix Computing, Ineffable Intelligence, and Callosum, the latter of which secured a $100 million seed round with Sovereign AI participation. The government declined to comment on ongoing negotiations, and Potential Sciences did not respond to requests for comment. The move underscores London's push to keep high-potential AI firms anchored in the UK while supporting applications in health and life sciences.